KIR3DL3 Antibody Modulation for Immune Suppression Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The functions of KIR3DL3, a member of the KIR family, were previously unknown, and there is a need for targeted therapies to modulate its activity for treating autoimmune diseases, cancers, and transplant rejection.

Innovation Solution

Development of antibodies and immunogenic fragments that specifically bind to KIR3DL3, allowing for blocking or stimulating its function to treat autoimmune diseases, cancers, and transplant rejection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If KIR3DL3 function is blocked by antibodies or immunogenic fragments, then immune response is activated to treat cancers and infections, but immune suppression is reduced which may worsen autoimmune diseases and transplant rejection

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidautoimmune disease risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses antibodies or immunogenic fragments as intermediary substances that specifically bind to KIR3DL3 to modulate its function. These intermediaries enable selective activation or suppression of immune response depending on the therapeutic need, allowing treatment of cancers and infections while managing autoimmune disease risks through controlled intervention

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If KIR3DL3 function is stimulated by antibodies or immunogenic fragments, then immune suppression is enhanced to treat autoimmune diseases and transplant rejection, but immune activation is reduced which may worsen cancers and infections

Engineering Contradiction:

Improveautoimmune disease treatment efficacyVSAvoidcancer progression risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs dynamic modulation of KIR3DL3 function where antibodies or immunogenic fragments can be administered at different doses, frequencies, and combinations to adaptively control immune suppression levels. This dynamic approach allows enhancement of immune suppression for autoimmune diseases and transplant rejection while minimizing the risk of cancer progression through flexible treatment adjustment

Inventive Principle:

Principle #15Dynamics

3Adaptability or versatility

If antibodies or immunogenic fragments are developed to specifically bind KIR3DL3, then targeted therapy is achieved for modulating immune response, but treatment complexity increases due to need for different therapies for different conditions

Engineering Contradiction:

Improvetargeted therapy capabilityVSAvoidtreatment regimen complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent develops antibodies or immunogenic fragments with universal binding capability to KIR3DL3 that can serve multiple therapeutic functions. The same binding agent can be used for different indications (cancers, infections, autoimmune diseases, transplant rejection) by adjusting administration parameters, thereby reducing overall treatment complexity while maintaining targeted therapy capability across different conditions

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12534527B2KIR3DL3 is an inhibitory receptor of the immune system and uses thereof

Publication Date: 2026.01.27 ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV

AI summary

Described herein are antibodies, immunogenic fragments and compositions thereof targeting the killer-cell immunoglobulin-like receptor protein KIR3DL3, as well as methods of using the same for the treatment of human diseases including cancer. In certain embodiments, the disclosure relates to an antibody or an immunogenic fragment thereof that specifically binds to KIR3DL3 protein, wherein the antibody or the immunogenic fragment thereof specifically binds to a KIR3DL3 epitope comprising the whole extracellular domain or a portion thereof.